MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments

被引：0
|
作者：
Heleen Scheerens
Zheng Su
Bryan Irving
Michael J Townsend
Yanan Zheng
Eric Stefanich
Vishala Chindalore
Clifton O Bingham
John C Davis
机构：
[1] Genentech Research and Early Development,Allergy and Clinical Immunology
[2] 1 DNA Way,undefined
[3] Pinnacle Research Center Anniston Medical Clinic PC,undefined
[4] Johns Hopkins University,undefined
来源：
Arthritis Research & Therapy | / 13卷
关键词：
rheumatoid arthritis; pharmacodynamics; phase I; antibody;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis - A double-blind, randomized, placebo-controlled trial
    van Dongen, Henrike
    van Aken, Jill
    Lard, Leroy R.
    Visser, Karen
    Ronday, H. Karel
    Hulsmans, Harry M. J.
    Speyer, Irene
    Westedt, Marie-Louise
    Peeters, Andre J.
    Allaart, Cornelia F.
    Toes, Rene E. M.
    Breedveld, Ferdinand C.
    Huizinga, Tom W. J.
    ARTHRITIS AND RHEUMATISM, 2007, 56 (05): : 1424 - 1432
  • [22] Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial
    Choy, EHS
    Panayi, GS
    Emery, P
    Madden, S
    Breedveld, FC
    Kraan, MC
    Kalden, JR
    Rascu, A
    Brown, JCC
    Rapson, N
    Johnston, JM
    RHEUMATOLOGY, 2002, 41 (10) : 1142 - 1148
  • [23] Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study
    Visvanathan, Sudha
    Daniluk, Stefan
    Ptaszynski, Rafal
    Mueller-Ladner, Ulf
    Ramanujam, Meera
    Rosenstock, Bernd
    Eleftheraki, Anastasia G.
    Vinisko, Richard
    Petrikova, Alena
    Kellner, Herbert
    Dokoupilova, Eva
    Kwiatkowska, Brygida
    Alten, Rieke
    Schwabe, Christian
    Baum, Patrick
    Joseph, David
    Fine, Jay S.
    Padula, Steven J.
    Steffgen, Juergen
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (06) : 754 - 760
  • [24] Efficacy and Safety of Ketoprofen Patch in Patients With Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled Study
    Kawai, Shinichi
    Uchida, Eiji
    Kondo, Masakazu
    Ohno, Syuji
    Obata, Junichi
    Nawata, Yasushi
    Sugimoto, Kazunori
    Oribe, Motohiro
    Nagaya, Ikuo
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (10): : 1171 - 1179
  • [25] EFFICACY AND SAFETY OF SM03, A RECOMBINANT ANTI-HUMAN CD22 MONOCLONAL ANTIBODY IN CHINESE PATIENTS WITH RHEUMATOID ARTHRITIS: A PHASE II RANDOMIZED, DOUBLE-BLIND, MULTIDOSE, PLACEBO-CONTROLLED STUDY
    Li, J.
    Li, M.
    Wu, D.
    Zhou, J.
    Leung, S. O.
    Zhang, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 131 - 131
  • [26] Zuberitamab, an innovative anti-CD20 monoclonal antibody, for patients with primary immune thrombocytopenia in China: a randomized, double-blind, placebo-controlled, phase 2 study
    Xu, Min
    Shu, Jinhui
    Qian, Shenxian
    Guo, Jingming
    Gong, Yuping
    Huang, Ruibin
    Wang, Shuye
    Zhou, Zeping
    Yuan, Guolin
    Huang, Meijuan
    Lin, Li -E
    Lou, Shifeng
    Song, Yanping
    Liu, Qingchi
    Zhou, Hu
    Mei, Heng
    Hu, Yu
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2024, 47
  • [27] Results of a placebo-controlled, multicenter trial using a primatized non-depleting, anti-CD4 monoclonal antibody in the treatment of rheumatoid arthritis.
    Levy, R
    Weisman, M
    Wiesenhutter, C
    Yocum, D
    Schnitzer, T
    Goldman, A
    Schiff, M
    Leiden, BF
    Solinger, A
    MacDonald, B
    Lipani, J
    ARTHRITIS AND RHEUMATISM, 1996, 39 (09): : 574 - 574
  • [28] Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, for Treatment of Rheumatoid Arthritis With an Inadequate Response to One or More Disease-Modifying Antirheumatic Drugs Results of a Randomized, Double-Blind, Placebo-Controlled, Phase I/II Study
    Ostergaard, Mikkel
    Baslund, Bo
    Rigby, William
    Rojkovich, Bernadette
    Jorgensen, Christian
    Dawes, Peter T.
    Wiell, Charlotte
    Wallace, Daniel J.
    Tamer, Soren C.
    Kastberg, Helle
    Petersen, Jorgen
    Sierakowski, Stanislaw
    ARTHRITIS AND RHEUMATISM, 2010, 62 (08): : 2227 - 2238
  • [29] DOCOSAHEXAENOIC ACID TREATMENT OF RHEUMATOID ARTHRITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSS-OVER STUDY
    Neumann, T.
    Dawczynski, C.
    Dittrich, M.
    Goetze, K.
    Welzel, A.
    Oelzner, P.
    Voelker, S.
    Schaible, A. M.
    Troisi, F.
    Thomas, L.
    Pace, S.
    Koeberle, A.
    Werz, O.
    Schlattmann, P.
    Lorkowski, S.
    Jahreis, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 115 - 115
  • [30] Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study
    Hasan Tahir
    Atul Deodhar
    Mark Genovese
    Tsutomu Takeuchi
    Jacob Aelion
    Filip Van den Bosch
    Sibylle Haemmerle
    Hanno B. Richards
    Rheumatology and Therapy, 2017, 4 : 475 - 488
12345